Hyperventilation

• But when we exercise, many of us become more aware of it than we normally are – sometimes thinking about every breath we take.
• During low and moderate-intensity exercises (such as walking and cycling), the majority of us breathe in through our nose and out through our mouths.
• But the more intense the exercise becomes, the more we tend to breathe entirely through our mouths.
• But evidence shows the contrary – and that breathing through your nose may actually be a better technique to use during intense exercise (such as running).
• A series of studies have shown that when exercising at different intensities, less oxygen is used when breathing through the nose compared to breathing through your mouth.
• This means the heart is under no additional stress when breathing through your nose during exercise.

• Gaps in swimming lessons, lifeguard shortages and climate change may make water-based activities even riskier this summer.
• Swimming pool closures at the start of the COVID-19 pandemic led to millions of Canadians missing swimming lessons.
• With facilities now open across Canada, parents are having great difficulty enrolling their children in the limited swimming lessons that are currently available.

Lessons and lifeguards

• However, the evidence on the value of swimming lessons in drowning prevention is not particularly strong.
• In fact, some researchers have asserted that lessons might give parents a false sense of security, resulting in them not closely supervising their children.
• So while there is concern about the lack of swimming lessons available to Canadians, an underrated drowning risk is swimming in unsupervised areas.
• In Canada, fewer than one per cent of drownings occur in areas supervised by swimming instructors or lifeguards.

Dangerous swimming

• As supervised hours at beaches and swimming pools are scaled back due to staff shortages, and the climate heats up, more people may turn to swimming in new or unsupervised locations to cool off.
• People swimming in unfamiliar areas may not be aware of hidden hazards, like drop-offs or rocks, or be unfamiliar with rip currents.
• Cold water can also be a danger, even during heatwaves in the summer months.
• Experts suggest that water below 21 C can be dangerous.
• Audrey R. Giles receives funding from the Social Sciences and Humanities Research Council of Canada and Transport Canada's Boating Safety Contribution Program.

• Alba Tull has made a generous donation of $500,000 to the Rett Syndrome Research Trust (RSRT) for a clinical study to determine the ability of the Emerald biosensor to accurately measure Rett syndrome symptoms, a key factor necessary for assessing the efficacy of drugs and genetic medicines.
• TRUMBULL, Conn., Feb. 7, 2023 /PRNewswire-PRWeb/ -- Alba Tull has made a generous donation of $500,000 to the Rett Syndrome Research Trust (RSRT) for a clinical study to determine the ability of the Emerald biosensor to accurately measure Rett syndrome symptoms, a key factor necessary for assessing the efficacy of drugs and genetic medicines.
• The Emerald sensor has been used in drug development in Alzheimer's and Parkinson's; this generous gift allows for testing its efficacy in Rett syndrome.
• "RSRT continues to set and drive Rett syndrome research, and this donation is a reflection of my confidence in their singular mission to cure Rett," said Tull.

• QDENGA is the only dengue vaccine approved in Indonesia for use in individuals regardless of previous dengue exposure and without the need for pre-vaccination testing.1
  Dengue can affect anyone living in or traveling to endemic areas - regardless of age, health and socio-economic circumstances, said Gary Dubin, president of Takedas Vaccine Business Unit.
• The TIDES trial met its primary endpoint of overall vaccine efficacy (VE) against virologically-confirmed dengue (VCD) with 80.2% efficacy at 12-months follow-up.
• 6 Tricou, V. Efficacy and Safety of Takedas Tetravalent Dengue Vaccine Candidate (TAK-003) After 4.5 Years of Follow-Up.
• Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo controlled, phase 3 trial.